List of Brukinsa drug patents

Brukinsa is owned by Beigene.

Brukinsa contains Zanubrutinib.

Brukinsa has a total of 4 drug patents out of which 0 drug patents have expired.

Brukinsa was authorised for market use on 14 November, 2019.

Brukinsa is available in capsule;oral dosage forms.

Brukinsa can be used as for the treatment of patients with waldenstrom's macroglobulinemia; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, for the treatment of patients with waldenstrom's macroglobulinemia; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; for the treatment of patients with waldenstrom's macroglobulinemia; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen.

Drug patent challenges can be filed against Brukinsa from November, 2023.

The generics of Brukinsa are possible to be released after 15 August, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in